ArticleFrontiers in medicine2025
Burden of cataracts in developing countries: a trend analysis based on data from China, 1990 to 2021.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advances in cataract surgery: is a new era on the horizon?Current opinion in ophthalmology · 2026Review
- Comparative Trends in the Burden of Depressive Disorders in China and Globally, 1990-2021: Evidence From the Global Burden of Disease 2021.Alpha psychiatry · 2026Article
- Deep learning-driven approach for cataract management: towards precise identification and predictive analytics.Frontiers in cell and developmental biology · 2025Review
- Assessing the relationship between gout and the risk of cataract in community-dwelling older adults: mediation and moderation analysis.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the trends in cataract-related blindness and vision impairment burden among cataract patients in China, the largest developing country, from 1990 to 2021, providing evidence to inform future cataract prevention and control strategies in developing countries. Patients and methods: This study utilized data from the Global Burden of Disease (GBD) 2021 database to assess the prevalence, age-standardized prevalence rates (ASPR), and years lived with disability (YLDs) associated with cataract-related blindness and visual impairment in China and other regions from 1990 to 2021. Joinpoint regression, decomposition analysis, and ARIMA modeling were employed to analyze trends and predict future disease burden. Results: From 1990 to 2021, the number and crude rate for cataract related blindness and visual impairment increasing significantly in China. The age-standardizes rate increased from 878.30 to 989.58 per 100,000 population for cataract prevalence, and from 73.40 to 61.39 per 100,000 population for cataract YLDs. The majority of number of prevalence and YLDs are concentrated in the 65-89 age range. Women had higher cataract prevalence and YLDs than men. Population aging is the primary driver of the growing burden of cataract, contributing 73.12% and 98.3% to the increases in prevalence and YLDs, respectively. By 2035, the crude prevalence rate and crude YLDs rate of cataracts are projected to increase by 26.06% and 23.03%, respectively, compared to 2021. The age-standardized prevalence and YLDs rate attribute to cataract in China were lower than global averages and ranked third among neighboring countries. Conclusion: Despite advancements in cataract treatment that have alleviated some of the disease burden, population growth and aging continue to drive the increasing prevalence of cataract-related vision impairment in China. Addressing gender disparities and improving access to cataract surgery and preventive care are crucial for reducing this growing burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.